SAN FRANCISCO--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company today announced interim results from 32 patients treated to date in a phase I clinical trial of ADCETRIS (brentuximab vedotin) administered in combination with or sequentially with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma (sALCL) and other CD30-positive mature T-cell lymphoma patients. The data are being presented at the T-Cell Lymphoma Forum being held January 26-28, 2012 in San Francisco, CA. ADCETRIS is not approved for use in front-line mature T-cell lymphoma.
